Clinical Trial Update: Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study [NA]

View source ↗

Summary

This is a single-arm, single-center clinical study evaluating multimodal ablation in combination with a PD-1 monoclonal antibody, lenvatinib, and transarterial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• PD-1 monoclonal antibody (unspecified) (PD-1 monoclonal antibody)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial | NA | Status: NOT_YET_RECRUITING